On July 30, the U.S. Food and Drug Administration (FDA) approved Azedra (iobenguane I 131) injection for intravenous use for the treatment of adults and adolescents age 12 and older with rare tumors of the adrenal gland (pheochromocytoma or paraganglioma) that are unresectable, have metastasized, and require systemic anticancer therapy.

Read more via U.S. Food and Drag Administration.